US$ 21.34
glp 1 agonists on the market GLP-1 Weight Loss Drugs Report, 2025-2030 GLP-1 Receptor Agonist Market Size
Description
Keep out of reach of children under 18

Some studies, though not conclusive, predict that tirzepatide may in fact be more potent than GLP-1 RAs at reducing weight

Earlier this year, Blue Cross Blue Shield said five GLP-1 drugs now account for nearly 20% of its pharmacy spend.

Find out here.

A new FDA-approved obesity pill could offer a lower-cost alternative to injectable GLP-1 drugs like Ozempic and Mounjaro
